ADAPTIVE BIOTECHNOLOGIES COR's ticker is ADPT and the CUSIP is 00650F109. A total of 199 filers reported holding ADAPTIVE BIOTECHNOLOGIES COR in Q2 2020. The put-call ratio across all filers is 0.51 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $57,688 | -18.7% | 10,585 | 0.0% | 0.04% | -13.3% |
Q2 2023 | $70,919 | -24.1% | 10,585 | 0.0% | 0.04% | -28.6% |
Q1 2023 | $93,466 | +18.5% | 10,585 | 0.0% | 0.06% | +3.3% |
Q4 2022 | $78,842 | +2.4% | 10,585 | -1.5% | 0.06% | +1.7% |
Q3 2022 | $77,000 | -9.4% | 10,747 | 0.0% | 0.06% | -1.6% |
Q2 2022 | $85,000 | -44.1% | 10,747 | 0.0% | 0.06% | -34.4% |
Q1 2022 | $152,000 | -49.7% | 10,747 | 0.0% | 0.09% | -47.8% |
Q4 2021 | $302,000 | -18.6% | 10,747 | -1.4% | 0.18% | -21.6% |
Q3 2021 | $371,000 | -14.3% | 10,897 | +2.9% | 0.23% | -14.0% |
Q2 2021 | $433,000 | +0.7% | 10,587 | 0.0% | 0.26% | -1.1% |
Q1 2021 | $430,000 | -35.9% | 10,587 | +1.6% | 0.27% | -35.0% |
Q4 2020 | $671,000 | +32.3% | 10,425 | 0.0% | 0.41% | +16.1% |
Q3 2020 | $507,000 | +0.6% | 10,425 | 0.0% | 0.35% | -31.5% |
Q2 2020 | $504,000 | +50.4% | 10,425 | 0.0% | 0.52% | +48.6% |
Q1 2020 | $335,000 | +4087.5% | 10,425 | +3690.9% | 0.35% | +5700.0% |
Q4 2019 | $8,000 | – | 275 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 2,377,665 | $12,958,274 | 12.23% |
Eagle Health Investments LP | 1,214,860 | $6,620,987 | 1.46% |
Matrix Capital Management Company, LP | 11,572,590 | $63,070,616 | 0.76% |
Aristotle Atlantic Partners, LLC | 3,058,206 | $16,667,223 | 0.67% |
VIKING GLOBAL INVESTORS LP | 29,993,708 | $163,465,709 | 0.66% |
Pier Capital, LLC | 719,067 | $3,918,915 | 0.63% |
DDD Partners, LLC | 783,697 | $3,385,571 | 0.49% |
ARK Investment Management | 11,509,308 | $62,725,728 | 0.48% |
Nikko Asset Management Americas, Inc. | 6,570,939 | $35,680,199 | 0.43% |
Triatomic Management LP | 102,889 | $560,745 | 0.39% |